Arterial stiffness in cancer survivors: the prognostic value of estimated pulse wave velocity (ePWV) in U.S cancer population from NHANES 2009-2018

Mustafa Hussein Ajlan Al-Jarshawi, Akhmetzhan Maratovich Galimzhanov, Marco Zimarino, Islam Y. Elgendy, Carlos Diaz‐Arocutipa, Ofer M. Kobo, Mamas A. Mamas

2025

Closed access Metadata (CSL-JSON)
DOI 10.1093/eurheartjsupp/suaf083.026
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Abstract Background Estimated pulse wave velocity (ePWV), a novel non-invasive marker of arterial stiffness, is strongly associated with cardiovascular (CV) events and all-cause mortality in the general population [1-3]. However, its prognostic potential in cancer survivors remains unexplored. This study evaluates the association of ePWV with all-cause and CV mortality and identifies an optimal ePWV threshold for risk stratification in cancer survivors. Methods Using 10 years of data from the National Health and Nutrition Examination Survey (NHANES, 2009-2018), we analysed a cohort representing over 105 million U.S. cancer survivors. Multivariate Cox regression and Kaplan-Meier analyses assessed the association between baseline ePWV and mortality, with adjustments for key demographic factors (age, sex, race/ethnicity), socioeconomic variables (income, education, marital status), body parameters (body mass index and pulse rate), traditional CV risk factors (hypertension, diabetes mellitus, hyperlipidemia, smoking history), and baseline CV disease status (heart failure, myocardial infarction, stroke). Dose-dependent relationships were explored using restricted cubic splines, and an optimal ePWV threshold was determined through maximally selected rank statistics. Results A total of 105,869,670 weighted cancer survivors (2,234 unweighted) were analysed, recording 435 all-cause and 91 CV deaths, equating to 14,979,486 weighted all-cause deaths and 3,174,609 weighted cardiovascular deaths, respectively. Early vascular aging (EVA, ePWV ≥9.4 m/s) was present in 54.6% of participants, with rectal cancer survivors showing the highest prevalence (88.3%), followed by prostate (80.2%) and bladder (78.6%) cancers. Each 1 m/s increase in ePWV was associated with higher risks of all-cause mortality (29%) and CV mortality (46%) (aHR, 95% CI of 1.29 [1.19–1.40] and 1.46 [1.20–1.76], respectively, both p < 0.001). Those with ePWV ≥ 12.05 m/s demonstrated significantly higher risks of all-cause and CV mortality (aHR, 95% CI of 1.70 [1.35–2.13] and 2.53 [1.56–4.12], respectively, both p < 0.001). Conclusion Arterial stiffness, assessed by ePWV, demonstrates prognostic utility in cancer survivors, showing a positive, non-linear association with long-term all-cause and CV mortality, independent of demographic, socioeconomic, traditional CV risk factors, and baseline CV disease status.